Abstract
The Development of Small Animal Models for Zika Virus Vaccine Efficacy Testing and Pathological Assessment.
Highlights
Most importantly, these immunocompromised mouse models demonstrated disease and viremia after infection with a low-passage Zika virus (ZIKV) strain, negating the necessity for passage adaptation for the elicitation of virulence
Previous attempts to develop ZIKV murine models involved the serial passage of the prototype strain in mice,[6] complicating the assessment of the effects of passage on virulence
Passage adaptation can alter the antigenicity of the resultant virus, obscuring any assessment of immunization with a circulating strain of ZIKV from which a candidate vaccine is likely to be generated
Summary
These immunocompromised mouse models demonstrated disease and viremia after infection with a low-passage ZIKV strain, negating the necessity for passage adaptation for the elicitation of virulence. Division of VectorBorne Diseases, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
